Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Osilodrostat and Cabergoline Versus Osilodrostat Alone in Cushing's Disease
NCT07603466Phase 4Enrolling by invitation
- Sponsor
- University of Basrah
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cabergoline in Cushing's disease (CD), sponsored by University of Basrah. Started May 2026; status: enrolling by invitation.
02
Drugs
cabergoline
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT07603466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07603466.